• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diagn Interv Radiol . Chest computed tomography radiomics to predict the outcome for patients with COVID-19 at an early stage

tetano

Editor, Senior Moderator
Diagn Interv Radiol


. 2023 Jan 31;29(1):91-102.
doi: 10.5152/dir.2022.21576. Epub 2023 Jan 18.
Chest computed tomography radiomics to predict the outcome for patients with COVID-19 at an early stage


Shan Wu[SUP] 1 [/SUP], Ranying Zhang[SUP] 2 [/SUP], Xinjian Wan[SUP] 1 [/SUP], Ting Yao[SUP] 3 [/SUP], Qingwei Zhang[SUP] 4 [/SUP], Xiaohua Chen[SUP] 3 [/SUP], Xiaohong Fan[SUP] 5 [/SUP]



Affiliations

Abstract

Purpose: Early monitoring and intervention for patients with novel coronavirus disease-2019 (COVID-19) will benefit both patients and the medical system. Chest computed tomography (CT) radiomics provide more information regarding the prognosis of COVID-19.
Methods: A total of 833 quantitative features of 157 COVID-19 patients in the hospital were extracted. By filtering unstable features using the least absolute shrinkage and selection operator algorithm, a radiomic signature was built to predict the prognosis of COVID-19 pneumonia. The main outcomes were the area under the curve (AUC) of the prediction models for death, clinical stage, and complications. Internal validation was performed using the bootstrapping validation technique.
Results: The AUC of each model demonstrated good predictive accuracy [death, 0.846; stage, 0.918; complication, 0.919; acute respiratory distress syndrome (ARDS), 0.852]. After finding the optimal cut-off for each outcome, the respective accuracy, sensitivity, and specificity were 0.854, 0.700, and 0.864 for the prediction of the death of COVID-19 patients; 0.814, 0.949, and 0.732 for the prediction of a higher stage of COVID-19; 0.846, 0.920, and 0.832 for the prediction of complications of COVID-19 patients; and 0.814, 0.818, and 0.814 for ARDS of COVID-19 patients. The AUCs after bootstrapping were 0.846 [95% confidence interval (CI): 0.844-0.848] for the death prediction model, 0.919 (95% CI: 0.917-0.922) for the stage prediction model, 0.919 (95% CI: 0.916-0.921) for the complication prediction model, and 0.853 (95% CI: 0.852-0.0.855) for the ARDS prediction model in the internal validation. Based on the decision curve analysis, the radiomics nomogram was clinically significant and useful.
Conclusion: The radiomic signature from the chest CT was significantly associated with the prognosis of COVID-19. A radiomic signature model achieved maximum accuracy in the prognosis prediction. Although our results provide vital insights into the prognosis of COVID-19, they need to be verified by large samples in multiple centers.

Keywords: COVID-19; Radiomic signature; prediction; prognosis.
 
Back
Top Bottom